Galderma lifted its full-year 2026 sales guidance following record first-half net sales of $3.134 billion, a material beat that reflects accelerating demand across its injectable and device portfolios. The Swiss aesthetics-focused company's H1 performance was driven by strong uptake of Botox, Juvéderm, and Sculptra, alongside growing contribution from its energy-device business.